You've come to the right place
The Hypertrophic Cardiomyopathy (HCM) Center and Research Institute at Tufts Medical Center is the largest, oldest and most experienced multi-disciplinary HCM program in Boston, the eastern United States, and one of only a few in the world.
At Tufts Medical Center, we create relationships with each and every patient and deliver the most up-to-date information about this disease. This is particularly important since there are common misunderstandings in the community and a new diagnosis of HCM can be intimidating.
Patients should know HCM is a disease that is compatible with normal longevity. In terms of the overall risks of living, conveys far less of a risk than other cardiac diseases like congestive heart failure (by 20-fold), myocardial infarction (by 10-fold) and virtually any cancer (by 35-fold).
We are a premier Center of Excellence and referral and treatment center for HCM, offering the complete spectrum of advanced diagnostic and therapeutic options. and were one of the first sites nationally to be designated as an HCM Center of Excellence—the highest rating given by the Hypertrophic Cardiomyopathy Association (HCMA).
Our most important goal is to provide all HCM patients and their family members the opportunity to achieve excellent quality of life. Our physicians and caregivers are HCM experts who are committed to clearly communicated care and empowering patients to make the best treatment decisions.
Tufts MC is a major surgical center for HCM
Only a minority of patients with HCM require surgery (septal myectomy). This method is the preferred treatment for patients with severe symptoms who are unresponsive to medications. When surgery is necessary, the HCM Center at Tufts MC has one of the most experienced and effective surgical programs to relieve obstruction to outflow and alleviate symptoms in a wide range of patients.
Over the past 15 years, Dr. Hassan Rastegar, has successfully operated on 900 severely symptomatic patients, achieving low risk and high success in restoring normal lifestyle to 95% of patients. Dr. Michael Robich focuses on surgical management of hypertrophic cardiomyopathy and heart valve surgery.
If you are considering surgical myectomy and/or your cardiologist has mentioned it to you for consideration, schedule an appointment with any of our experts to learn more.
For more information about the results of septal myectomy surgery, read an article by the HCM team at Tufts MC.
Misconceptions about HCM
Hypertrophic cardiomyopathy (HCM) is a relatively common genetic heart disease that has been encumbered throughout much of its history by large amounts of misunderstanding as well as the perception that it has a grim outcome and lacks effective treatment options. Many patients with HCM mistakenly consider their diagnosis to be among the least favorable they could confront.
However, it is now apparent the majority of affected HCM patients can achieve normal or near-normal life expectancy without disability, and usually do not require major treatment interventions. For those HCM patients who are at risk for (or experience) disease-related complications, there are a constellation of comprehensive management strategies that have evolved over the last 15 years and altered the disease course for many. These clinical management initiatives provide many patients with reassurance and a reasonable expectation for extended (if not normal) longevity that exceeds that of many other non-cardiac diseases.